HOME / Notice / News / EN
On June 28, the 'JTC Group of Companies ' visited NKCL Bio Group. NKCL Biogroup has explained its technological competitiveness of NK cell therapy, which is spotlighted as a next-generation anticancer treatment, to the 'JTC Group of Companies', and shared the future vision regarding the growth of imm...
On the 20th, the Cambodian economic delegation, the Reachsey Association, visiting Korea at the moment, visited NKCL Bio Group Inc. and announced that they discussed ways to cooperate in the bio industry between the two countries. The Cambodian economic delegation to Korea, the Reachsey Association, ...
NKCL Bio Group Inc. (Chairman Dong-Hwa Shin, hereinafter referred to as NKCL) announced that it had acquired a ‘T-4’ grade, an excellent company certification at Technology Credit Bureau(TCB) by NICE evaluation information, a nationally accredited technology credit rating agency. The Tech Credit Bu...
On the 9th, NKCL Bio Group Inc.’s Chairman Dong-Hwa Shin has won the grand prize in the ‘2022 Korea’s Influential CEO- Innovative Management Bio Sector’ hosted by TV Chosun and Digital Chosun Ilbo. The '2022 Korea's Influential CEO' is awarded among the CEOs of companies and institutions during t...
NKCL Bio Group Inc. announced on the 3rd that it had obtained the 'T-5' grade, an excellent company certification from the 'SCI’ Tech Credit Bureau, a technology credit evaluation company. The Tech Credit Bureau comprehensively analyzes and evaluates a company's technological prowess, such as techno...